Literature DB >> 7473655

Congenital anomalies and genetic disorders in families of children with central nervous system tumours.

S M Jones1, P C Phillips, P T Molloy, B J Lange, M N Needle, J A Biegel.   

Abstract

Medical genetic histories of 165 children with primary central nervous system (CNS) tumours and 4599 relatives of these probands were examined to identify birth defects or genetic disorders that may be associated with the aetiology of CNS tumours. Twelve primary malignancies were found in 329 (4%) of the parents of probands. Two of 99 half sibs but no full sibs had malignancies. Twenty-four percent of families had histories warranting consultation for an inherited disorder or birth defect. Single instances of malformations or genetic disorders were reported in 36 families and several disorders were reported in more than one family, including familial hypercholesterolaemia (4), olivopontocerebellar atrophy (2), and familial abdominal aortic aneurysm (2). Although recurring abnormalities were not identified in probands, it is possible that one or more of the birth defects or genetic disorders observed in probands or relatives may be associated with CNS tumourigenesis.

Entities:  

Mesh:

Year:  1995        PMID: 7473655      PMCID: PMC1051638          DOI: 10.1136/jmg.32.8.627

Source DB:  PubMed          Journal:  J Med Genet        ISSN: 0022-2593            Impact factor:   6.318


  31 in total

1.  Frequent somatic mutations and loss of heterozygosity of the von Hippel-Lindau tumor suppressor gene in primary human renal cell carcinomas.

Authors:  T Shuin; K Kondo; S Torigoe; T Kishida; Y Kubota; M Hosaka; Y Nagashima; H Kitamura; F Latif; B Zbar
Journal:  Cancer Res       Date:  1994-06-01       Impact factor: 12.701

2.  Identification of the von Hippel-Lindau disease tumor suppressor gene.

Authors:  F Latif; K Tory; J Gnarra; M Yao; F M Duh; M L Orcutt; T Stackhouse; I Kuzmin; W Modi; L Geil
Journal:  Science       Date:  1993-05-28       Impact factor: 47.728

Review 3.  The role of gene mutations in the genesis of familial cancers.

Authors:  C Eng; B A Ponder
Journal:  FASEB J       Date:  1993-07       Impact factor: 5.191

Review 4.  The neurofibromatosis type 1 gene and its protein product, neurofibromin.

Authors:  D H Gutmann; F S Collins
Journal:  Neuron       Date:  1993-03       Impact factor: 17.173

5.  Two cases of 5q deletions in patients with familial adenomatous polyposis: possible link with Caroli's disease.

Authors:  S V Hodgson; A S Coonar; P J Hanson; S Cottrell; P N Scriven; T Jones; P R Hawley; M L Wilkinson
Journal:  J Med Genet       Date:  1993-05       Impact factor: 6.318

Review 6.  The role of WT1 in Wilms tumorigenesis.

Authors:  M J Coppes; C E Campbell; B R Williams
Journal:  FASEB J       Date:  1993-07       Impact factor: 5.191

Review 7.  Genetic mechanisms of solid tumor oncogenesis.

Authors:  M J Kelley; B E Johnson
Journal:  Adv Intern Med       Date:  1994

8.  von Hippel-Lindau disease: identification of deletion mutations by pulsed-field gel electrophoresis.

Authors:  M Yao; F Latif; M L Orcutt; I Kuzmin; T Stackhouse; F W Zhou; K Tory; F M Duh; F Richards; E Maher
Journal:  Hum Genet       Date:  1993-12       Impact factor: 4.132

9.  Mutations of the VHL tumour suppressor gene in renal carcinoma.

Authors:  J R Gnarra; K Tory; Y Weng; L Schmidt; M H Wei; H Li; F Latif; S Liu; F Chen; F M Duh
Journal:  Nat Genet       Date:  1994-05       Impact factor: 38.330

Review 10.  Antioncogenes and human cancer.

Authors:  A G Knudson
Journal:  Proc Natl Acad Sci U S A       Date:  1993-12-01       Impact factor: 11.205

View more
  2 in total

Review 1.  Clinical manifestations of genetic instability overlap one another.

Authors:  Károly Méhes; György Kosztolányi
Journal:  Pathol Oncol Res       Date:  2004-03-18       Impact factor: 3.201

2.  Congenital neurodevelopmental anomalies in pediatric and young adult cancer.

Authors:  Jeannette R Wong-Siegel; Kimberly J Johnson; Katie Gettinger; Nicole Cousins; Nicole McAmis; Ashley Zamarione; Todd E Druley
Journal:  Am J Med Genet A       Date:  2017-08-29       Impact factor: 2.802

  2 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.